Oxadiazole transient receptor potential channel inhibitors

A compound of formula (I):

• wherein:
• (i) A is selected from
• (ii) X is selected from a bond, C1-4 alkylene, —O—, —S—, —SO2—, and —N(R1)—, wherein R1 is selected from H and C1-6 alkyl;
• (iii) B is selected from:
• (a) substituted and unsubstituted C4-6 cycloalkyl wherein, when substituted, the bond to the oxadiazole moiety and the bond to the substituent are on other than adjacent ring carbon atoms;
• (b) substituted and unsubstituted fused bicyclic bound to the oxadiazole moiety by a carbon-carbon bond;
• and
• (c) substituted and unsubstituted fused tricyclic;
• (iv) E is a five membered or a six membered heteroaryl ring wherein one ring carbon atom is optionally substituted with oxo;
• (v) G is a six membered heteroaryl ring having one ring carbon atom substituted with oxo;
• (vi) one of Y1, Y2, Y3 and Y4 is —C(O)—, one to three of Y1, Y2, Y3, Y4, Y5 and Y6 are nitrogen, and the other of Y1, Y2, Y3, Y4, Y5 and Y6 are carbon;
• (vii) one or two of Z1, Z2, Z3, Z4 and Z5 are nitrogen and the other of Z1, Z2, Z3, Z4 and Z5 are carbon;
• (viii) each R2 is independently selected from H, deuterium, —C1-4 alkyl, —C1-4haloalkyl, —CN, halo, C1-4 haloalkoxy, C1-4 alkoxy, —OH, —SO2—C1-4alkyl, —C1-4CN, C1-4 aldehyde, C1-4 ketone, and —NR14R15, and p is 0, 1 or 2, wherein R14 and R15 are independently selected from H, substituted and unsubstituted —C1-4 alkyl, substituted and unsubstituted —C(O)—C1-4 alkyl, substituted and unsubstituted C3-6 cycloalkyl, substituted and unsubstituted 3- to 6-membered heterocycloalkyl, substituted and unsubstituted —C1-4 heteroalkyl, and substituted and unsubstituted —C1-4 alkyl-C(O)NR16R17 wherein R16 and R17 are independently selected from H and C1-4 alkyl;
• and
• (ix) R3 is selected from H, —C1-4 alkyl, —C1-4 haloalkyl, —CN, and halo, and q is 0 or 1;
• or a pharmaceutical salt thereof.